Ragaa H. M. Salama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ragaa H. M. Salama has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Abd El Rahman G Ramadan
1 shared publicationAbd-Elmoneim A. Elhagagy
Urology Department, Faculty of medicine, Assiut University, Assiut, Egypt
1 shared publicationAbdel-Raheim M. Mekki
1 shared publicationAbdullah Alghasham
1 shared publicationAhmed Abbas
1 shared publicationAhmed Y. A. Nassar
Department of Medical Biochemistry, Faculty of Medicine, Assiut University, Assuit, Egypt
1 shared publication
Latest Publications
- 20 May 2023
- Published by China Scientific Research Publishing Pte. Ltd. in JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
- Vol. 37 (5) , 2819-2828
Immune Modulation of Inflammasome Stimulates NLRP3 and IL-1β Expression in Preeclampsia: Insights into the Role of Anti-Inflammatory Agents in Prevention of Low Birth Weight
Background: Preeclampsia remains a leading cause of maternal and neonatal morbidity and mortality. It is characterized by altered local and systemic immune regulation and a rise in proinflammatory cytokines. The inflammasome is a cytosolic protein complex that mediates innate immune responses through promoting the secretion of interleukin-1beta (IL-1β). This study aimed to investigate the nucleotide oligomerization domain (NOD)-like receptor family, pyrin domain-containing protein 3, inflammasome activation in preeclampsia (PE), its relation to IL-1β and their association with PE outcomes. Methods: Placenta and blood were collected from 25 control pregnant women and 50 preeclamptic women. Pyrin domain-containing protein 3 (NLRP3) and IL-1β gene expression were quantified by real-time polymerase chain reaction (PCR). Results: Placental and blood relative gene expression levels of NLRP3 and IL-1β were significantly higher in mild and severe PE than in controls. A significantly higher blood expression of NLRP3 was noticed in the low birth weight subgroup compared to the normal birth weight subgroup (p = 0.03) in the severe PE group. Both biomarkers levels in placenta and blood showed significant negative correlations with the weight of newborn. The strong positive correlation (p < 0.0001, r = 0.9) between NLRP3 and IL-1β suggested that IL-1β response mostly depend on NLRP3 inflammasome. Conclusions: These results suggest the presence of excessive activation of NLRP3 and subsequently increased production of active IL-1β that may predispose placental inflammation in severe PE and subsequently, low neonatal birth weight and shortened gestational age.
- 20 May 2023
- Published by China Scientific Research Publishing Pte. Ltd. in JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
- Vol. 37 (5) , 2819-2828
Immune Modulation of Inflammasome Stimulates NLRP3 and IL-1β Expression in Preeclampsia: Insights into the Role of Anti-Inflammatory Agents in Prevention of Low Birth Weight
Background: Preeclampsia remains a leading cause of maternal and neonatal morbidity and mortality. It is characterized by altered local and systemic immune regulation and a rise in proinflammatory cytokines. The inflammasome is a cytosolic protein complex that mediates innate immune responses through promoting the secretion of interleukin-1beta (IL-1β). This study aimed to investigate the nucleotide oligomerization domain (NOD)-like receptor family, pyrin domain-containing protein 3, inflammasome activation in preeclampsia (PE), its relation to IL-1β and their association with PE outcomes. Methods: Placenta and blood were collected from 25 control pregnant women and 50 preeclamptic women. Pyrin domain-containing protein 3 (NLRP3) and IL-1β gene expression were quantified by real-time polymerase chain reaction (PCR). Results: Placental and blood relative gene expression levels of NLRP3 and IL-1β were significantly higher in mild and severe PE than in controls. A significantly higher blood expression of NLRP3 was noticed in the low birth weight subgroup compared to the normal birth weight subgroup (p = 0.03) in the severe PE group. Both biomarkers levels in placenta and blood showed significant negative correlations with the weight of newborn. The strong positive correlation (p < 0.0001, r = 0.9) between NLRP3 and IL-1β suggested that IL-1β response mostly depend on NLRP3 inflammasome. Conclusions: These results suggest the presence of excessive activation of NLRP3 and subsequently increased production of active IL-1β that may predispose placental inflammation in severe PE and subsequently, low neonatal birth weight and shortened gestational age.
- 1 January 2022
- Published by Egyptian Knowledge Bank in The Egyptian Journal of Hospital Medicine
- Vol. 86 (1) , 413-419
Osteoprotegerin, Soluble Receptor Activator Nuclear Factor-κB Ligand, Nuclear Factor Kappa B and Intestinal Trefoil Factor 3 are Promising Biomarkers in Diagnosis and Follow- up Inflammatory Bowel Disease Patients
Background: Inflammatory bowel disease (IBD) is a condition in which the gastrointestinal system becomes inflamed for no apparent reason. Its incidence increased during the last few decades. As a result, it's critical to understand how to validate a clinical diagnosis and monitor any progress using a simple procedure. Osteoprotegerin (OPG), which interacts with RANKL, regulates RANK/RANKL signaling. OPG is a decoy receptor for soluble receptor activator of nuclear factor-B ligand (sRANKL), which stimulates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and the healing trefoil factor 3 (TFF3), which could be employed as in the diagnosis and follow-up of IBD patients, biomarkers are used. Objectives: The aim of the current work was to evaluate the role of RANKL (sRANKL), OPG, NF-κB , and TFF3 in in the diagnosis of active IBD. Subjects and methods: Thirty-five newly diagnosed untreated IBD patients and thirty-five healthy controls were included in this study. Patients were then given particular treatment either in the form of cortisone, mesalamin, immunotherapy or infliximab and immunotherapy for 3 months and attend for second visit. OPG, sRANKL, NF-κB and TFF3 levels were estimated by ELISA method using commercial kits in patients before and after treatment and healthy control. Results: Patients with IBD had significantly increased levels of OPG, sRANKL, NF-B, and TFF3 than healthy controls (P =0.0001). After 3 months of treatment, patients' levels of NF-B and TFF3 were significantly lower (p = 0.0001 and 0.03, respectively). Conclusion: The biomarkers OPG, sRANKL, NF-κB , and TFF3 show promise in the diagnosis of active IBD. The decrease in NF-κB and TFF3 following treatment suggests that be used as biomarkers to track disease activity and treatment effectiveness.
- 1 January 2022
- Published by Egyptian Knowledge Bank in The Egyptian Journal of Hospital Medicine
- Vol. 86 (1) , 413-419
Osteoprotegerin, Soluble Receptor Activator Nuclear Factor-κB Ligand, Nuclear Factor Kappa B and Intestinal Trefoil Factor 3 are Promising Biomarkers in Diagnosis and Follow- up Inflammatory Bowel Disease Patients
Background: Inflammatory bowel disease (IBD) is a condition in which the gastrointestinal system becomes inflamed for no apparent reason. Its incidence increased during the last few decades. As a result, it's critical to understand how to validate a clinical diagnosis and monitor any progress using a simple procedure. Osteoprotegerin (OPG), which interacts with RANKL, regulates RANK/RANKL signaling. OPG is a decoy receptor for soluble receptor activator of nuclear factor-B ligand (sRANKL), which stimulates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and the healing trefoil factor 3 (TFF3), which could be employed as in the diagnosis and follow-up of IBD patients, biomarkers are used. Objectives: The aim of the current work was to evaluate the role of RANKL (sRANKL), OPG, NF-κB , and TFF3 in in the diagnosis of active IBD. Subjects and methods: Thirty-five newly diagnosed untreated IBD patients and thirty-five healthy controls were included in this study. Patients were then given particular treatment either in the form of cortisone, mesalamin, immunotherapy or infliximab and immunotherapy for 3 months and attend for second visit. OPG, sRANKL, NF-κB and TFF3 levels were estimated by ELISA method using commercial kits in patients before and after treatment and healthy control. Results: Patients with IBD had significantly increased levels of OPG, sRANKL, NF-B, and TFF3 than healthy controls (P =0.0001). After 3 months of treatment, patients' levels of NF-B and TFF3 were significantly lower (p = 0.0001 and 0.03, respectively). Conclusion: The biomarkers OPG, sRANKL, NF-κB , and TFF3 show promise in the diagnosis of active IBD. The decrease in NF-κB and TFF3 following treatment suggests that be used as biomarkers to track disease activity and treatment effectiveness.
- Open Access
- 28 October 2019
- Published by Madridge Publishers, LLC in International Journal of Biochemistry and Pharmacology
- Vol. 1 (1) , 21-26
Experimental and Therapeutic Trials of Amygdalin
International Journal of Biochemistry and Pharmacology(IJBP)
- 28 October 2019
- Published by Madridge Publishers, LLC in International Journal of Biochemistry and Pharmacology
- Vol. 1 (1) , 21-26
Open AccessExperimental and Therapeutic Trials of Amygdalin
International Journal of Biochemistry and Pharmacology(IJBP)
- 2 October 2012
- Published by Springer Nature in Indian Journal of Clinical Biochemistry
- Vol. 28 (4) , 368-373
Clinical and Biochemical Effects of Environmental Tobacco Smoking On Pregnancy Outcome
- 2 October 2012
- Published by Springer Nature in Indian Journal of Clinical Biochemistry
- Vol. 28 (4) , 368-373
Clinical and Biochemical Effects of Environmental Tobacco Smoking On Pregnancy Outcome
- 2 October 2012
- Published by Springer Nature in Indian Journal of Clinical Biochemistry
- Vol. 28 (3) , 265-271
Urinary Tumor Markers Could Predict Survival in Bladder Carcinoma
- 2 October 2012
- Published by Springer Nature in Indian Journal of Clinical Biochemistry
- Vol. 28 (3) , 265-271
Urinary Tumor Markers Could Predict Survival in Bladder Carcinoma
- 1 July 2012
- Published by Elsevier in Clinical Biochemistry
- Vol. 45 (10-11) , 766-769
Bone morphogenetic protein-2 will be a novel biochemical marker in urinary tract infections and stone formation
- 1 July 2012
- Published by Elsevier in Clinical Biochemistry
- Vol. 45 (10-11) , 766-769
Bone morphogenetic protein-2 will be a novel biochemical marker in urinary tract infections and stone formation
- Open Access
- 1 January 2012
- Published by Medknow in Saudi Journal of Kidney Diseases and Transplantation
- Vol. 23 (4) , 765-72
Matricaria chamomilla attenuates cisplatin nephrotoxicity
Matricaria chamomilla is extensively consumed as a tea or tonic. Despite its widespread use as a home remedy, relatively few trials evaluated its benefits in nephro protection. Hence, this study evaluates the protective role of M. chamomilla in cisplatin nephrotoxicity rat model. The study was conducted on 32 rats divided into four groups. The first group (G1) was injected with saline intra-peritoneally (IP); G2 was injected with 5 mg/kg cisplatin on day 0 of the experiment and repeated four times, with five days free interval. G3 and G4 were injected daily with M. chamomilla (50 mg/kg) IP, starting five days before the experiment (-5 day); in addition, G4 was injected with cisplatin. On day 16, animals were scarified and serum and/or kidney tissue was used to determine: (a) kidney function tests (serum urea, creatinine, gamma glutamyl transferase (GGT), NAG, β-gal), (b) oxidative stress indices (NO, LPO), (c) antioxidant activities (SOD, GSH, total thiols), (d) apoptotic indices (Cathepsin D, DNA fragmentation) and (e) mineral (calcium). M. chamomilla significantly increased the body weight, normalized the kidney functions, improved the apoptotic markers, reduced the oxidative stress markers and corrected the hypo-calcemia that resulted from cisplatin nephrotoxicity. M. chamomilla is a promising nephro-protective compound reducing cisplatin nephrotoxicity most probably by its antioxidant activities and inhibition of gamma glutamyl transferase activity.
- 1 January 2012
- Published by Medknow in Saudi Journal of Kidney Diseases and Transplantation
- Vol. 23 (4) , 765-72
Open AccessMatricaria chamomilla attenuates cisplatin nephrotoxicity
Matricaria chamomilla is extensively consumed as a tea or tonic. Despite its widespread use as a home remedy, relatively few trials evaluated its benefits in nephro protection. Hence, this study evaluates the protective role of M. chamomilla in cisplatin nephrotoxicity rat model. The study was conducted on 32 rats divided into four groups. The first group (G1) was injected with saline intra-peritoneally (IP); G2 was injected with 5 mg/kg cisplatin on day 0 of the experiment and repeated four times, with five days free interval. G3 and G4 were injected daily with M. chamomilla (50 mg/kg) IP, starting five days before the experiment (-5 day); in addition, G4 was injected with cisplatin. On day 16, animals were scarified and serum and/or kidney tissue was used to determine: (a) kidney function tests (serum urea, creatinine, gamma glutamyl transferase (GGT), NAG, β-gal), (b) oxidative stress indices (NO, LPO), (c) antioxidant activities (SOD, GSH, total thiols), (d) apoptotic indices (Cathepsin D, DNA fragmentation) and (e) mineral (calcium). M. chamomilla significantly increased the body weight, normalized the kidney functions, improved the apoptotic markers, reduced the oxidative stress markers and corrected the hypo-calcemia that resulted from cisplatin nephrotoxicity. M. chamomilla is a promising nephro-protective compound reducing cisplatin nephrotoxicity most probably by its antioxidant activities and inhibition of gamma glutamyl transferase activity.
- Open Access
- 1 January 2011
- Published by S. Karger AG in Medical Principles and Practice
- Vol. 20 (2) , 124-128
Implication of Umbilical Cord in Preeclampsia
Objectives: To investigate the role of biochemical changes in the umbilical cord and placenta in developing preeclampsia (PE). Subjects and Methods: Thirty women with PE and 15 healthy pregnant women as controls were enrolled in this study. Vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor 1 (sVEGFR-1), platelet-derived endothelial cell growth factor (PD-ECGF), neutrophil elastase and nitric oxide (NO) were measured. Results: Both serum (maternal and fetal) and tissue (placenta and umbilical cord) levels of VEGF, sVEGFR-1, PD-ECGF and neutrophil elastase were significantly increased, whereas NO was significantly decreased (except placental tissue showed no changes) in preeclamptic patients. The cord serum level of PD-ECGF was significantly higher in severe PE compared to mild PE and normal pregnant women. The placental and cord tissue levels of PD-ECGF and neutrophil elastase were significantly higher in severe PE, while the cord tissue level of NO was significantly lower in severe PE. Conclusion: Our data showed that umbilical cord vessels and stroma can serve as an additional source of vasoactive and angiogenic substances that contribute to the biochemical changes occurring in PE.
- 1 January 2011
- Published by S. Karger AG in Medical Principles and Practice
- Vol. 20 (2) , 124-128
Open AccessImplication of Umbilical Cord in Preeclampsia
Objectives: To investigate the role of biochemical changes in the umbilical cord and placenta in developing preeclampsia (PE). Subjects and Methods: Thirty women with PE and 15 healthy pregnant women as controls were enrolled in this study. Vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor 1 (sVEGFR-1), platelet-derived endothelial cell growth factor (PD-ECGF), neutrophil elastase and nitric oxide (NO) were measured. Results: Both serum (maternal and fetal) and tissue (placenta and umbilical cord) levels of VEGF, sVEGFR-1, PD-ECGF and neutrophil elastase were significantly increased, whereas NO was significantly decreased (except placental tissue showed no changes) in preeclamptic patients. The cord serum level of PD-ECGF was significantly higher in severe PE compared to mild PE and normal pregnant women. The placental and cord tissue levels of PD-ECGF and neutrophil elastase were significantly higher in severe PE, while the cord tissue level of NO was significantly lower in severe PE. Conclusion: Our data showed that umbilical cord vessels and stroma can serve as an additional source of vasoactive and angiogenic substances that contribute to the biochemical changes occurring in PE.
- 9 March 2007
- Published by Wiley in Liver International
- Vol. 27 (4) , 454-464
A novel therapeutic drug (copper nicotinic acid complex) for non‐alcoholic fatty liver
Background: Fatty liver is the accumulation of fat in liver cells, which leads to disruption of the normal liver structure and function.Methods: A non‐alcoholic fatty liver rat model received copper (Cu) (I)‐nicotinate complex [CuCl(HNA)2] for 4 weeks.Results: Clinical signs and histopathological examinations showed obvious improvements in rats that received Cu complex who were continuously on an (HCFF) diet than those returned to standard diet with Cu complex. The improvement was matched in total lipids in sera and hepatic tissue, with disappearance of fat droplets from liver sections. Furthermore, the gain in body weight and the corresponding decrease in liver weight, decreased liver transaminases and alkaline phosphatase were prominent. The oxidative stress markers such as nitric oxide, lipid peroxides, glutathione and superoxide dismutase were obviously changed to healthy normal levels.Conclusion: The Cu complex may serve as a novel chemical restoring agent in fatty degenerated liver cells and for renewal of their structure and functions. However, clinical trials are required for more evaluation of the Cu complex in humans.
- 9 March 2007
- Published by Wiley in Liver International
- Vol. 27 (4) , 454-464
A novel therapeutic drug (copper nicotinic acid complex) for non‐alcoholic fatty liver
Background: Fatty liver is the accumulation of fat in liver cells, which leads to disruption of the normal liver structure and function.Methods: A non‐alcoholic fatty liver rat model received copper (Cu) (I)‐nicotinate complex [CuCl(HNA)2] for 4 weeks.Results: Clinical signs and histopathological examinations showed obvious improvements in rats that received Cu complex who were continuously on an (HCFF) diet than those returned to standard diet with Cu complex. The improvement was matched in total lipids in sera and hepatic tissue, with disappearance of fat droplets from liver sections. Furthermore, the gain in body weight and the corresponding decrease in liver weight, decreased liver transaminases and alkaline phosphatase were prominent. The oxidative stress markers such as nitric oxide, lipid peroxides, glutathione and superoxide dismutase were obviously changed to healthy normal levels.Conclusion: The Cu complex may serve as a novel chemical restoring agent in fatty degenerated liver cells and for renewal of their structure and functions. However, clinical trials are required for more evaluation of the Cu complex in humans.